- 39
- 17 964
Cereno Scientific
Sweden
เข้าร่วมเมื่อ 15 ธ.ค. 2021
Cereno Scientific is a Swedish-based clinical-stage biotech company in cardiovascular disease. The company focuses on developing innovative treatments for patients affected by common and rare cardiovascular diseases. Cereno's portfolio of clinical and preclinical drug candidates has the potential to completely change the way cardiovascular disease is treated today.
Cereno Scientific presents positive topline results of Phase IIa trial with CS1 in PAH
Cereno Scientific presents positive topline results of Phase IIa trial with CS1 in PAH
มุมมอง: 577
วีดีโอ
Dr. Michael Holinstat presents new preclinical data for CS585 at ESC Congress 2024
มุมมอง 27328 วันที่ผ่านมา
Dr. Michael Holinstat presents new preclinical data for CS585 at ESC Congress 2024
Cereno Scientific at ESC 2024
มุมมอง 804หลายเดือนก่อน
Cereno Scientific are at the ESC Congress in London, organized by the European Society of Cardiology. This is the most important congress of the year, where 35 000 people meet with a common goal to improve the lives of people suffering from cardiovascular disease.
Insights Series S3E9: Cereno leading the way in HDAC inhibitors for CVD
มุมมอง 4526 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3E8: Dr. Björn Dahlöf on HDAC inhibitors as an important potential therapy for CVD
มุมมอง 3136 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3E7: Dr. Raymond Benza on Pulmonary Arterial Hypertension - Cereno at PVRI
มุมมอง 3186 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Life Sciencedagen 2024
มุมมอง 4836 หลายเดือนก่อน
Cereno presented at Life Sciencedagen, March 6 2024, in Gothenburg CEO Sten R. Sörensen and CMO and Head of R&D Rahul Agrawal, presented the company portfolio, the role of HDAC inhibition and disease-modifying properties of CS1 in PAH, gave an overview of thrombosis prevention with CS014, and an introduction to the preclinical program CS585.
Insights Series S3 E6: Dr. Raymond Benza on HDAC inhibition in PAH
มุมมอง 3537 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insight Series S3 E5: Dr. Raymond Benza on Compassionate Use
มุมมอง 5087 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3 E4: CEO Sten R. Sörensen about the future implications for PAH patients
มุมมอง 4447 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3 E3: CEO Sten R. Sörensen on the exciting field of PAH
มุมมอง 3957 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3 E2: CEO Sten R. Sörensen on “Compassionate use”
มุมมอง 4367 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S3 E1: CEO Sten R. Sörensen about the latest news for Cereno Scientific
มุมมอง 4497 หลายเดือนก่อน
English subtitles are available. (Recorded at PVRI 2024 Annual Congress in January)
Insights Series S2E8: Prof Benza about the move towards innovative trial designs in PAH studies
มุมมอง 5038 หลายเดือนก่อน
Raymond L. Benza, Chief of Pulmonary Hypertension at Mount Sinai Health System, New York City, Principal Investigator of the Phase II study of CS1, and member of Cereno’s Scientific Advisory Board, speaks about how the industry moves toward innovative trial designs in pulmonary arterial hypertension (PAH) studies. English subtitles are available. This video is episode 8 in the Insights Series s...
Insights Series S2E7: Prof Benza about the rationale and design of a Phase II clinical trial in PAH
มุมมอง 5788 หลายเดือนก่อน
Raymond L. Benza, System Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City, Principal Investigator of the Phase II study of CS1, and member of Cereno’s Scientific Advisory Board, speaks about the rationale and design of the Phase 2 clinical trial in PAH with drug candidate CS1, a controlled-release formulation of valproic acid. The video further provides ...
Insights Series S2E6: P.Adamson, Abbott, on enhancing quality of life for patients with CardioMEMS™
มุมมอง 3869 หลายเดือนก่อน
Insights Series S2E6: P.Adamson, Abbott, on enhancing quality of life for patients with CardioMEMS™
Insights Series S2E5: Phil Adamson, Abbott, about personalized medicine in PAH with CardioMEMS™
มุมมอง 46511 หลายเดือนก่อน
Insights Series S2E5: Phil Adamson, Abbott, about personalized medicine in PAH with CardioMEMS™
Insights Series S2E4: Phil Adamson, Abbott, about CardioMEMS™ use in the CS1 clinical trial
มุมมอง 42911 หลายเดือนก่อน
Insights Series S2E4: Phil Adamson, Abbott, about CardioMEMS™ use in the CS1 clinical trial
Insights Series S2E3: P.Adamson, Abbott, on CardioMEMS and its utility in the study of heart failure
มุมมอง 380ปีที่แล้ว
Insights Series S2E3: P.Adamson, Abbott, on CardioMEMS and its utility in the study of heart failure
Insights Series S2E2: Prof. Benza about why CS1 is such an exciting drug candidate in PAH
มุมมอง 700ปีที่แล้ว
Insights Series S2E2: Prof. Benza about why CS1 is such an exciting drug candidate in PAH
Insights Series S2E1: Prof. Benza on remarkable patient case study data from Phase II study of CS1
มุมมอง 1.1Kปีที่แล้ว
Insights Series S2E1: Prof. Benza on remarkable patient case study data from Phase II study of CS1
Cereno Scientific's Capital Markets Day 2023
มุมมอง 2.2Kปีที่แล้ว
Cereno Scientific's Capital Markets Day 2023
Cereno at ESC 2023: Our CEO speaks about the latest updates in our Phase II study of CS1 in PAH.
มุมมอง 348ปีที่แล้ว
Cereno at ESC 2023: Our CEO speaks about the latest updates in our Phase II study of CS1 in PAH.
ESC 2023 congress: Sten R. Sörensen, CEO, shares his take on the hottest news in Cereno right now
มุมมอง 114ปีที่แล้ว
ESC 2023 congress: Sten R. Sörensen, CEO, shares his take on the hottest news in Cereno right now
ESC 2023 congress: Our CMO Björn Dahlöf about the great opportunities that the congress brings
มุมมอง 97ปีที่แล้ว
ESC 2023 congress: Our CMO Björn Dahlöf about the great opportunities that the congress brings
Cereno at the ESC 2023 congress! Our CEO Sten R. Sörensen talks about the congress.
มุมมอง 90ปีที่แล้ว
Cereno at the ESC 2023 congress! Our CEO Sten R. Sörensen talks about the congress.
Insights Series: PAH and CardioMEMS collaboration from Abbott's perspective
มุมมอง 212ปีที่แล้ว
Insights Series: PAH and CardioMEMS collaboration from Abbott's perspective
Insights Series: Prof. Benza about Cereno's Clinical Phase II Trial with CS1
มุมมอง 227ปีที่แล้ว
Insights Series: Prof. Benza about Cereno's Clinical Phase II Trial with CS1
🚀
Cereno is pure gold!!
Cereno fast launch in indian
super duper
Go Cereno!
promo sm 😚
Awesome!
I belive Cereno is on the way to do something great! This is the company that will make an average Joe rich if you play your cards right. That’s just my thoughts. Not to mention the benefit for these ill patients.❤️
🔥🔥
Cereno is future gold!!💪
Go Cereno!
I belive Cs1 is something really unique. Will be exciting to see the result of the study and what a difference it could make for the PAH community.
I’m scare because I have chronic pulmonary artery hypertension 😞
Cereno Scientific @ BioStock Life Science Fall Summit | October 2023 th-cam.com/video/zcSUSAePjZc/w-d-xo.html
The remarkable advancements made with patient one showcase the excellence of this company's state-of-the-art scientific research
🔥
Truly remarkable progress on patient one, this company and its cutting edge science is a true gem!
Interesting video with very strong data from Cereno
remarkable
Amazing as Always!
Would really love if you guys uploaded more information on youtube regarding all three candidates. It really helps getting it on video, with someone explaining.
Hej! Vore tacksamt om ni kunde ladda upp fler klipp och information på er youtube kanal.